A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

Leukemia

Volumn 27, Issue 7, 2013, Pages 1479-1486

  Park, S ^a,b   Chapuis, N ^a,b   Saint Marcoux, F ^c   Recher, C ^d   Prebet, T ^e   Chevallier, P ^f   Cahn, J Y ^g   Leguay, T ^h   Bories, P ⁱ   Witz, F ^j   Lamy, T ^k   Mayeux, P ^b   Lacombe, C ^a,b   Demur, C ^d   Tamburini, J ^a,b   Merlat, A ^l   Delepine, R ^m   Vey, N ^e   Dreyfus, F ^a,b   Bene M C ^j   Ifrah, N ⁿ   Bouscary, D ^a,b   more..

^a Hôpital Cochin ^*  (France)

^b INSTITUT COCHIN   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e Hopital Paoli Calmettes   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l BU Oncologie Novartis Pharma SAS   (France)

^m CHU BRETONNEAU   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

AML; mTORC1; RAD001; Relapse

Indexed keywords

CYTARABINE; DAUNORUBICIN; EVEROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APLASIA; ARTERY THROMBOSIS; ARTICLE; ATAXIA; BACTEREMIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CONSTIPATION; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; KIDNEY FAILURE; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; TACHYCARDIA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880254610     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.17     Document Type: Article

References (39)

1. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011; 25: 39-51.
2. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14: 2009-2023.
3. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527-2534.
4. Recher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4: 1540-1549.
5. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-382.
6. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980.
7. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-4268.
8. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732-6739.
9. Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012; 156: 205-212.
10. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K et al. Dose- and scheduledependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
11. O'Donnell A, Faivre S, Burris 3rd HA, Rea D, Papadimitrakopoulou V, Shand N et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-1595.
12. Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24: 1380-1385.
13. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
14. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged o/60 years: results of a prospective multicenter trial. Ann Hematol 2004; 83: 336-344.
15. Goirand F, Royer B, Hulin A, Saint-Marcoux F. level of evidence for therapeutic drug monitoring of everolimus. Therapie 2011; 66: 57-61.
16. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006; 108: 3477-3483.
17. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010; 16: 5424-5435.
18. Martin Ramos ML, Lopez Pastor M, de la Serna Torroba J, Ayala R, Garcia Alonso L, Barreiro Miranda E. (Cytogenetic risk categories in acute myeloid leukemia: a comparison between MRC (Medical Research Council) and SWOG (Southwest Oncology Group) models)). Med Clin (Barc) 2003; 121: 121-125.
19. O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 2011; 22: 58-78.
20. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
21. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982; 60: 309-315.
22. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984; 53: 411-419.
23. Freund M, Link H, Diedrich H, LeBlanc S, Wilke HJ, Poliwoda H. High-dose ara-C and etoposide in refractory or relapsing acute leukemia. Cancer Chemother Pharmacol 1991; 28: 487-490.
24. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS. Acute myeloid leukemia in Manitoba. The consequences of standard "7+3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 1994; 74: 52-60.
25. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 1997; 79: 59-68.
26. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 45-51.
27. Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 175-187.
28. Monma F, Katayama N. (Management of microbial infections in myeloid leukemia). Nihon Rinsho 2009; 67: 1969-1973.
29. Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116: 103-112.
30. Perl AE, Kasner MT, Shank D, Luger SM, Carroll M. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 2012; 18: 1716-1725.
31. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012; 72: 6468-6476.
32. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894-1900.
33. Brincker H, Christensen BE. Long-term survival and late relapses in acute leukaemia in adults. Br J Haematol 1990; 74: 156-160.
34. Norkin M, Uberti JP, Schiffer CA. Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leuk Res 2011; 35: 139-144.
35. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma 2010; 51: 778-782.
36. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.
37. Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 2010; 9: 292.
38. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
39. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114: 1618-1627.